Information Provided By:
Fly News Breaks for June 7, 2016
RGLS
Jun 7, 2016 | 10:38 EDT
Chardan Capital Markets analyst Madhu Kumar raised his price target for Regulus Therapeutics to $20 from $15 after the company announced results from the primary endpoint analysis of a phase IIa study of RG-101 for the treatment of chronic hepatitis C virus. RG-101 combination therapy at four weeks continues to demonstrate clinical efficacy as good or superior to twelve-week direct-acting antivirals therapies, Kumar tells investors in a research note. He keeps a Buy rating on Regulus. The stock is trading down 6c to $5.88 in morning trading.
News For RGLS From the Last 2 Days
There are no results for your query RGLS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.